The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng, +15

The Lancet Oncology

Cyclin-dependent Kinase 4/6Breast OncologyInhibitor PalbociclibMedicinePharmacology +9

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín, +80

Annals of Oncology

Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis

Katalin Boér, Katherine L. Vandemheen, Elizabeth Tullis, +8

Thorax

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Richard S. Finn, John Crown, Johannes Ettl, +13

Breast Cancer Research

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Richard S. Finn, Katalin Boér, Igor Bondarenko, +12

Breast Cancer Research and Treatment

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Jaafar Bennouna, István Láng, Manuel Valladares‐Ayerbes, +7

Investigational New Drugs

Phase IiGastrointestinal OncologyMedicinePharmacologyPathology +7

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

RS Finn, JP Crown, István Láng, +12

Cancer Research

Breast OncologyPharmacotherapyTumor BiologyRandomized Phase 2Pre-clinical Pharmacology +16

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi, +288

Annals of Oncology

Metastatic Breast CancerBreast OncologyMedicinePathologyPreliminary Safety +5

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Cristina Saura, Dominik Hlauschek, Mafalda Oliveira, +23

The Lancet Oncology

Breast OncologyEndocrine-related CancerTaselisib VersusMedicineGynecology +9

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi, +230

Annals of Oncology